PGEN PRECIGEN, INC.

Nasdaq precigen.com


$ 4.03 $ -0.28 (-6.4 %)    

Thursday, 20-Nov-2025 14:36:55 EST
QQQ $ 588.96 $ -22.71 (-3.71 %)
DIA $ 459.47 $ -7.21 (-1.54 %)
SPY $ 655.58 $ -17.32 (-2.57 %)
TLT $ 89.21 $ 0.22 (0.25 %)
GLD $ 375.36 $ 0.18 (0.05 %)
$ 4.22
$ 4.30
$ 4.03 x 400
$ 4.04 x 852
$ 4.00 - $ 4.47
$ 0.65 - $ 5.23
5,275,998
na
1.49B
$ 1.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-19-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-14-2024 03-31-2024 10-Q
8 03-19-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-06-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-13-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-09-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-01-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 02-29-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-precigen-raises-price-target-to-9

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Precigen (NASDAQ:PGEN) with a Buy and raises the price targ...

 precigen-q3-eps-106-misses-010-estimate-sales-2922m-beat-500000k-estimate

Precigen (NASDAQ:PGEN) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.10) by...

 precigen-reports-responses-to-papzimeos-in-adults-with-recurrent-respiratory-papillomatosis-reinforcing-fda-approval

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

 precigen-entered-into-a-credit-facility-agreement-with-pharmakon-advisors-for-up-125m-in-non-dilutive-funding

The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and condition...

 jmp-securities-maintains-market-outperform-on-precigen-raises-price-target-to-8

JMP Securities analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target...

 hc-wainwright--co-reiterates-buy-on-precigen-maintains-85-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $8.5 price...

 why-is-precigen-stock-surging-on-friday

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION